Genetic and biomarker approaches to uterine fibroids: toward precision medicine
Description
This is the peer-reviewed and published version of the preprint previously uploaded to Zenodo.
Uterine fibroids (UFs) are the most common benign tumors of the female reproductive
system, affecting 70–80% of women by age 50. Early detection is challenging due to the
absence of initial symptoms, and diagnosis primarily relies on ultrasound and magnetic
resonance imaging (MRI). However, biomarker-driven approaches could enable earlier
and more precise detection. This review explores emerging biomarkers and genetic
factors in fibroid pathogenesis. Potential biomarkers, including PLP1, FOS, versican,
LDH, and IGF-1, show promise for diagnosis and recurrence prediction. Genetic studies
have identified key mutations in MED12, FH, HMGA2, and COL4A5-COL4A6, alongside
genome-wide association studies (GWAS) that highlight fibroid risk loci. Interestingly,
biomarkers may also be mutation-type specific, suggesting potential for more precise
molecular classification. Gene therapy offers an innovative treatment approach but the
genetic landscape of fibroids remains underexplored, limiting advancements in research
and funding. Integrating biomarker-based diagnostics and genetic profiling could
transform fibroid detection and management, reducing reliance on invasive procedures.
This review highlights the urgent need for improved diagnostic tools, prognostic markers,
and targeted therapies for uterine fibroids.